Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Neuroplasticity01:01

Neuroplasticity

Neuroplasticity reflects the brain's remarkable capacity to adapt and evolve, responding dynamically to learning, experiences, or injury by reorganizing its neural circuitry. This reorganization involves creating new neural connections and refining old ones through a series of biological processes that contribute to the brain's lifelong development and adaptability.
CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Behavioral variant frontotemporal dementia: advanced disease stages and death. A step to palliative care.

International journal of geriatric psychiatry·2016
Same author

[Connections between sleep and Alzheimer's disease : Insomnia, amnesia and amyloid].

Der Nervenarzt·2016
Same author

[Mechanisms of Alzheimer's disease : Neuronal hyperactivity and hypoactivity as new therapeutic targets].

Der Nervenarzt·2016
Same author

[The burn-out syndrome: prevalence, symptoms, differential diagnosis and treatment].

Deutsche medizinische Wochenschrift (1946)·2014
Same author

Over-the-counter-drugs for the treatment of mood and anxiety disorders--the views of German pharmacists.

Pharmacopsychiatry·2014
Same author

Pathways and patterns of cell loss in verified Alzheimer's disease: a factor and cluster analysis of clinico-pathological subgroups.

Behavioural neurology·2014
Same journal

[When brain abscesses run in the family…].

Der Nervenarzt·2026
Same journal

[Digital health applications and adherence in depression: a qualitative study from the perspective of healthcare providers].

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
Same journal

[Rare genetic diseases with frequent mental symptoms].

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
See all related articles

Related Experiment Video

Updated: Jun 22, 2026

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

[Neuro-enhancement. Brain doping].

H Förstl1

  • 1Klinik und Poliklinik für Psychiatrie und Psychotherapie, Ismaningerstr. 22, 81675, München. hans.foerstl@lrz.tu-muenchen.de

Der Nervenarzt
|July 1, 2009
PubMed
Summary
This summary is machine-generated.

Cognitive enhancement drugs are being developed, but their long-term benefits and risks for healthy individuals remain unclear. Future research must examine potential neurobiological and psychosocial trade-offs and new diseases from sustained use.

More Related Videos

High-definition Transcranial Direct Current Stimulation over Right Dorsolateral Prefrontal Cortex to Enhance Metacognitive Sensitivity
06:11

High-definition Transcranial Direct Current Stimulation over Right Dorsolateral Prefrontal Cortex to Enhance Metacognitive Sensitivity

Published on: September 26, 2025

A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning
09:22

A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning

Published on: June 22, 2015

Related Experiment Videos

Last Updated: Jun 22, 2026

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

High-definition Transcranial Direct Current Stimulation over Right Dorsolateral Prefrontal Cortex to Enhance Metacognitive Sensitivity
06:11

High-definition Transcranial Direct Current Stimulation over Right Dorsolateral Prefrontal Cortex to Enhance Metacognitive Sensitivity

Published on: September 26, 2025

A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning
09:22

A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning

Published on: June 22, 2015

Area of Science:

  • Neuroscience and Pharmacology
  • Investigates the mechanisms and applications of cognitive enhancement interventions.

Context:

  • The field of cognitive enhancement is rapidly advancing with over 100 substances under development.
  • Existing and emerging drugs like cholinesterase inhibitors, methylphenidate, and modafinil are being explored for use in healthy populations.

Purpose:

  • To review the current landscape of cognitive enhancement.
  • To identify key neuropsychiatric questions requiring investigation before wider adoption of these substances.

Summary:

  • Numerous drugs are candidates for cognitive enhancement, but their efficacy and safety in healthy individuals require demonstration.
  • Key concerns include long-term disadvantages, rebound effects, psychosocial trade-offs, and potential for new neuropsychiatric diseases.
  • Novel strategies must prove superior to established methods like caffeine consumption.

Impact:

  • Highlights critical neuro-ethical and neuropsychiatric considerations for the future of cognitive enhancement.
  • Emphasizes the need for rigorous research to balance potential benefits against significant risks.